BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/6/2019 10:43:10 AM | Browse: 847 | Download: 1248
 |
Received |
|
2018-12-26 01:16 |
|
Peer-Review Started |
|
2018-12-27 07:54 |
|
To Make the First Decision |
|
2019-01-21 02:24 |
|
Return for Revision |
|
2019-01-27 03:41 |
|
Revised |
|
2019-02-23 09:07 |
|
Second Decision |
|
2019-03-15 08:59 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-03-16 22:48 |
|
Articles in Press |
|
2019-03-16 22:48 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-05-06 06:21 |
|
Publish the Manuscript Online |
|
2019-05-06 10:43 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ken Sato, Yuichi Yamazaki, Takeshi Kobayashi, Satoshi Takakusagi, Norio Horiguchi, Satoru Kakizaki, Masayasu Andou, Yoshihiro Matsuda, Toshio Uraoka, Hiroshi Ohnishi and Hiroaki Okamoto |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ken Sato, MD, PhD, Assistant Professor, Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Gunma, Japan. satoken@gunma-u.ac.jp |
| Key Words |
Direct-acting antiviral agent failure; Hepatitis C; Genotype 2; Ribavirin; Sofosbuvir; Case report |
| Core Tip |
The effectiveness of sofosbuvir/ribavirin (SOF/RBV) therapy was unknown for patients who experienced failure of ombitasvir/paritaprevir/ritonavir plus ribavirin therapy and had hepatitis C virus genotype 2. Although there were only 2 patients, SOF/RBV therapy was effective. However, both patients experienced adverse events including unanticipated development or deterioration of autoimmune diseases. Because SOF/RBV therapy is generally well-tolerated, one of the patients was considered a specific case. However, the cases suggest SOF/RBV therapy should be carefully applied in case of the existence of baseline autoimmune disease. Our case reports warrant future studies, but careful observation during and after treatment is required. |
| Publish Date |
2019-05-06 10:43 |
| Citation |
Sato K, Yamazaki Y, Kobayashi T, Satoshi Takakusagi S, Horiguchi N, Kakizaki S, Andou M, Matsuda Y, Uraoka T, Ohnishi H, Okamoto H. Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature. World J Clin Cases 2019; 7(9): 1043-1052 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i9/1043.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i9.1043 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
